Epicutaneous immunotherapy (skin patch)DBV Technologies

VIASKIN Peanut patch

The VIASKIN Peanut patch delivers controlled amounts of peanut protein through intact skin to desensitize allergic children. DBV is developing the 250 µg patch to reduce the severity of reactions on accidental exposure.

Also known as: VIASKIN Peanut, DBV712, Viaskin

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

VIASKIN Peanut patch forecasting benchmarks

1 benchmark

ResolvedPhase 3

VITESSE Phase 3: VIASKIN® Peanut patch 250 µg in peanut-allergic children aged 4–7 years

VIASKIN Peanut patch · Peanut allergy

Dec 16, 2025Clinical Trials

Indications studied

Peanut allergy

Developed by

DBV Technologies· DBV

About VIASKIN Peanut patch

What is VIASKIN Peanut patch?

What does VIASKIN Peanut patch target?

VIASKIN Peanut patch's mechanism is summarized above; see the linked trial readouts for details.

How well do AI models predict VIASKIN Peanut patch trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.